Antidepressants

Treatment-Resistant Depression: Clinical Conundrum

In this podcast episode, we take on the challenge of treatment-resistant depression and its therapeutic options. Dr. Philip Cowen (University of Oxford) provided insights for this clinical conundrum with a simple algorithm.

Read More

The Role of Serotonin (5-HT) in Impulsivity/Aggression, Anxiety/Stress and Cognition

This presentation reviews the effects of serotonin receptors (5-HTR) on domains such as impulsivity/aggression, anxiety/stress, and cognition. It also discusses findings from neuroimaging studies involving 5-HT1A and 5-HT2A receptors.

Read More

GAD Pharmacotherapy: Augmenting vs Switching in Partial Responders

This presentation discusses how to address partial response to pharmacotherapy in the treatment of GAD. When to switch and when to augment. Dr. Osser gives three options for augmentation.

Read More

GAD Pharmacotherapy: Addressing Comorbidities and Special Populations

This presentation discusses the pharmacotherapy of generalized anxiety disorder (GAD). More specifically, it summarizes how to treat comorbid conditions (bipolar disorder, PTSD, substance use, insomnia) and considerations in special populations (elderly and women of childbearing potential).

Read More

The Use of Psychotropics in Irritable Bowel Syndrome and Bariatric Surgery

What is the role of antidepressants in the treatment of irritable bowel syndrome? How is drug absorption affected after gastric bypass surgery? This presentation gives practical answers to these questions.

Read More

Are Drug Interaction Warnings Influenced by Drug Company Promotion? An Interview with Dr. Jeffrey Mattes

Dr. Jeffrey Mattes, psychiatrist in Princeton, New Jersey speaks about drug interaction warnings that appear during electronic prescribing and how these warnings may be influenced by drug company promotion.
This interview is part of a series covering the 2018 ASCP Annual Meeting.

Read More

SSRIs and Bleeding Risk: What Does the Evidence Say?

Do SSRIs increase bleeding risk? This presentation reviews what the current literature says on the risk of GI, perioperative, postpartum and cerebral bleeding with SSRI use.

Read More

Do Depression Efficacy Trials Apply to Your Clinical Practice? An Interview with Dr. Mark Zimmerman

Dr. Mark Zimmerman, professor of psychiatry and human behavior at Brown University, speaks about depression efficacy trials and their clinical implications.
This interview is part of a series covering the 2018 ASCP Annual Meeting.

Read More

Treatment-Resistant Depression: Augmentation with Second-Generation Antipsychotics (Aripiprazole vs Quetiapine)

Prof. Philip Cowen Professor of Psychopharmacology Department of Psychiatry University of Oxford, UK This presentation compares advantages and disadvantages of using quetiapine vs. aripiprazole as augmentation for treatment-resistant depression. It also addresses the common question of when to augment (antidepressant + SGA) vs. when to switch (prescribing a different antidepressant). Combination and Augmentation: Clarifying Concepts…

Read More

Inflammation and Depression: Use of Anti-Inflammatory Agents and The Role of Inflammatory Markers (CRP)

Prof. Philip Cowen Professor of Psychopharmacology Department of Psychiatry University of Oxford, UK This presentation summarizes recent findings on the role of inflammation in depression. A study suggests patients with elevated levels of inflammatory markers (C-reactive protein) have a differential response to a specific antidepressant. The efficacy of celecoxib and infliximab in treatment-resistant depression is…

Read More